Cen Junda built a multibillion-dollar pharmaceutical fortune through large ownership positions in Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group after training in the pharmaceutical field. [1][2][3]
Pharmaceutical training preceded major industry stakes
Cen Junda studied pharmaceuticals at Zhejiang University and also holds training from the China State Institute of Pharmaceutical Industry. Forbes identifies pharmaceuticals as the source of his fortune and classifies the wealth as self-made. [1][3]
His wealth is concentrated in two drugmakers rather than a diversified family conglomerate. Forbes attributes the fortune to stakes in Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group, both major Chinese pharmaceutical businesses. [1]
Hengrui's 2025 annual report identifies Cen as a substantial shareholder through controlled corporations, with an interest representing about 14% of the company's issued share capital. That position is one of the principal public assets behind his wealth. [2]
Hansoh added a second large pharmaceutical holding
Bloomberg reports that Cen's holding company Apex Medical was a founding shareholder of Hansoh Pharmaceutical Group in 2015 and that his Hansoh interest remains another major component of his net worth alongside Hengrui. [3]
The available record points to a fortune created through pharmaceutical ownership and investment rather than inheritance, but it gives less detail about how Cen accumulated his earliest Hengrui position than it does about the later Hansoh structure. That gap argues for some caution in assigning the very highest self-made score. [1][2][3]
Sources for background
Sources reviewed Oct 13, 2026.
- Cen Junda · Forbes · Mar 10, 2026
- Annual Report 2025 · Jiangsu Hengrui Pharmaceuticals · Mar 26, 2026
- Bloomberg Billionaires Index: Cen Junda · Bloomberg
Comparable Healthcare billionaires
Similar Healthcare billionaires by estimated net worth.
